Ultrasound contrast agents
This article was originally published in The Gray Sheet
Executive Summary
Imavist contrast agent, developed jointly by Alliance Pharmaceutical and Schering AG, will enter a favorable reimbursement environment following FDA approval, the firms note. In July, CMS created new APCs defining ultrasound contrast agents as drugs and making them eligible for outpatient prospective "pass-through" payments covering 95% of their average wholesale cost, Alliance explains. The company has submitted the documentation requested by FDA in its August 2000 "approvable" letter and expects to launch the product by year-end
You may also be interested in...
Alliance Touts Imagent Synthetic Heart Imaging Agent As Easier To Store
Alliance Pharmaceutical Corp. will launch its Imagent ultrasound heart imaging agent at the American Society of Echocardiography meeting in Orlando June 9-12
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.